Fifth Third Bancorp
VRDN icon

Fifth Third Bancorp’s Viridian Therapeutics VRDN Stock Holding History

Fifth Third Bancorp’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.81K Sell
208
-98
-32% -$1.58K ﹤0.01% 3989
2026
Q1 		$5.97K Buy
+306
New +$9.09K ﹤0.01% 3819

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fifth Third Bancorp's VRDN Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Viridian Therapeutics (VRDN) stake by 32% in Q2 2026, selling an estimated $1.58K and leaving 208 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #3989.

Fifth Third Bancorp first reported a position in VRDN in Q1 2026 and has held it in 2 quarters since. The position peaked at $5.97K in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Fifth Third Bancorp held 208 shares of Viridian Therapeutics worth $3.81K as of Q2 2026.
  • Fifth Third Bancorp sold 98 Viridian Therapeutics shares in Q2 2026, an estimated $1.58K.
  • Viridian Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3989 holding.
  • Fifth Third Bancorp first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Fifth Third Bancorp's Viridian Therapeutics position peaked at $5.97K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.